Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S]
The mechanism by which cholesteryl ester transfer protein (CETP) activity affects HDL metabolism was investigated using agents that selectively target CETP (dalcetrapib, torcetrapib, anacetrapib). In contrast with torcetrapib and anacetrapib, dalcetrapib requires cysteine 13 to decrease CETP activit...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2010-12-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520313559 |
id |
doaj-6b0ce888f3634531a2b4ff3ba44e3457 |
---|---|
record_format |
Article |
spelling |
doaj-6b0ce888f3634531a2b4ff3ba44e34572021-04-28T05:57:31ZengElsevierJournal of Lipid Research0022-22752010-12-01511234433454Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S]Eric J. Niesor0Christine Magg1Naoto Ogawa2Hiroshi Okamoto3Elisabeth von der Mark4Hugues Matile5Georg Schmid6Roger G. Clerc7Evelyne Chaput8Denise Blum-Kaelin9Walter Huber10Ralf Thoma11Philippe Pflieger12Makoto Kakutani13Daisuke Takahashi14Gregor Dernick15Cyrille Maugeais16To whom correspondence should be addressed. eric_j.niesor@roche.com; Pharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandCentral Pharmaceutical Research Institute, Japan Tobacco, Inc., Osaka, JapanCentral Pharmaceutical Research Institute, Japan Tobacco, Inc., Osaka, JapanPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandCentral Pharmaceutical Research Institute, Japan Tobacco, Inc., Osaka, JapanCentral Pharmaceutical Research Institute, Japan Tobacco, Inc., Osaka, JapanPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandThe mechanism by which cholesteryl ester transfer protein (CETP) activity affects HDL metabolism was investigated using agents that selectively target CETP (dalcetrapib, torcetrapib, anacetrapib). In contrast with torcetrapib and anacetrapib, dalcetrapib requires cysteine 13 to decrease CETP activity, measured as transfer of cholesteryl ester (CE) from HDL to LDL, and does not affect transfer of CE from HDL3 to HDL2. Only dalcetrapib induced a conformational change in CETP, when added to human plasma in vitro, also observed in vivo and correlated with CETP activity. CETP-induced pre-β-HDL formation in vitro in human plasma was unchanged by dalcetrapib ≤3 µM and increased at 10 µM. A dose-dependent inhibition of pre-β-HDL formation by torcetrapib and anacetrapib (0.1 to 10 µM) suggested that dalcetrapib modulates CETP activity. In hamsters injected with [3H]cholesterol-labeled autologous macrophages, and given dalcetrapib (100 mg twice daily), torcetrapib [30 mg once daily (QD)], or anacetrapib (30 mg QD), only dalcetrapib significantly increased fecal elimination of both [3H]neutral sterols and [3H]bile acids, whereas all compounds increased plasma HDL-[3H]cholesterol. These data suggest that modulation of CETP activity by dalcetrapib does not inhibit CETP-induced pre-β-HDL formation, which may be required to increase reverse cholesterol transport.http://www.sciencedirect.com/science/article/pii/S0022227520313559dalcetrapibtorcetrapibanacetrapibhigh density lipoprotein-functionalityapolipoproteinsbile acids and salts/metabolism |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Eric J. Niesor Christine Magg Naoto Ogawa Hiroshi Okamoto Elisabeth von der Mark Hugues Matile Georg Schmid Roger G. Clerc Evelyne Chaput Denise Blum-Kaelin Walter Huber Ralf Thoma Philippe Pflieger Makoto Kakutani Daisuke Takahashi Gregor Dernick Cyrille Maugeais |
spellingShingle |
Eric J. Niesor Christine Magg Naoto Ogawa Hiroshi Okamoto Elisabeth von der Mark Hugues Matile Georg Schmid Roger G. Clerc Evelyne Chaput Denise Blum-Kaelin Walter Huber Ralf Thoma Philippe Pflieger Makoto Kakutani Daisuke Takahashi Gregor Dernick Cyrille Maugeais Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S] Journal of Lipid Research dalcetrapib torcetrapib anacetrapib high density lipoprotein-functionality apolipoproteins bile acids and salts/metabolism |
author_facet |
Eric J. Niesor Christine Magg Naoto Ogawa Hiroshi Okamoto Elisabeth von der Mark Hugues Matile Georg Schmid Roger G. Clerc Evelyne Chaput Denise Blum-Kaelin Walter Huber Ralf Thoma Philippe Pflieger Makoto Kakutani Daisuke Takahashi Gregor Dernick Cyrille Maugeais |
author_sort |
Eric J. Niesor |
title |
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S] |
title_short |
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S] |
title_full |
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S] |
title_fullStr |
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S] |
title_full_unstemmed |
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S] |
title_sort |
modulating cholesteryl ester transfer protein activity maintains efficient pre-β-hdl formation and increases reverse cholesterol transport[s] |
publisher |
Elsevier |
series |
Journal of Lipid Research |
issn |
0022-2275 |
publishDate |
2010-12-01 |
description |
The mechanism by which cholesteryl ester transfer protein (CETP) activity affects HDL metabolism was investigated using agents that selectively target CETP (dalcetrapib, torcetrapib, anacetrapib). In contrast with torcetrapib and anacetrapib, dalcetrapib requires cysteine 13 to decrease CETP activity, measured as transfer of cholesteryl ester (CE) from HDL to LDL, and does not affect transfer of CE from HDL3 to HDL2. Only dalcetrapib induced a conformational change in CETP, when added to human plasma in vitro, also observed in vivo and correlated with CETP activity. CETP-induced pre-β-HDL formation in vitro in human plasma was unchanged by dalcetrapib ≤3 µM and increased at 10 µM. A dose-dependent inhibition of pre-β-HDL formation by torcetrapib and anacetrapib (0.1 to 10 µM) suggested that dalcetrapib modulates CETP activity. In hamsters injected with [3H]cholesterol-labeled autologous macrophages, and given dalcetrapib (100 mg twice daily), torcetrapib [30 mg once daily (QD)], or anacetrapib (30 mg QD), only dalcetrapib significantly increased fecal elimination of both [3H]neutral sterols and [3H]bile acids, whereas all compounds increased plasma HDL-[3H]cholesterol. These data suggest that modulation of CETP activity by dalcetrapib does not inhibit CETP-induced pre-β-HDL formation, which may be required to increase reverse cholesterol transport. |
topic |
dalcetrapib torcetrapib anacetrapib high density lipoprotein-functionality apolipoproteins bile acids and salts/metabolism |
url |
http://www.sciencedirect.com/science/article/pii/S0022227520313559 |
work_keys_str_mv |
AT ericjniesor modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT christinemagg modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT naotoogawa modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT hiroshiokamoto modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT elisabethvondermark modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT huguesmatile modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT georgschmid modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT rogergclerc modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT evelynechaput modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT deniseblumkaelin modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT walterhuber modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT ralfthoma modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT philippepflieger modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT makotokakutani modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT daisuketakahashi modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT gregordernick modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports AT cyrillemaugeais modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports |
_version_ |
1721504842682204160 |